Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
H. Verbaan, L. Bondeson & S. Eriksson. (1997) Non-Invasive Assessment of Inflammatory Activity and Fibrosis (Grade and Stage) in Chronic Hepatitis C Infection. Scandinavian Journal of Gastroenterology 32:5, pages 494-499.
Read now
Read now
Renate Seelig, M. Renz, Claudia Bottner & H. P. Seelig. (1994) Hepatitis C Virus Infections in Dialysis Units: Prevalence of HCV-RNA and Antibodies to HCV. Annals of Medicine 26:1, pages 45-52.
Read now
Read now
Y. Nakano, K. Kiyosawa, T. Sodeyama, E. Tanaka, K. Yoshizawa, K. Furuta, Y. Nakatsuji, A. Urushihara & S. Furuta. (1993) Anti-c100 Antibodies to Hepatitis C Virus in Patients with Chronic Hepatitis C Virus Infection Treated with Interferon. Scandinavian Journal of Gastroenterology 28:4, pages 335-342.
Read now
Read now
Articles from other publishers (43)
Gary L. Davis. 2012. Chronic Hepatitis C Virus. Chronic Hepatitis C Virus
3
11
.
Gary L. Davis, Miriam J. Alter, Hashem El–Serag, Thierry Poynard & Linda W. Jennings. (2010) Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology 138:2, pages 513-521.e6.
Crossref
Crossref
Uwe Siebert, Gaby Sroczynski, Pamela Aidelsburger, Siegbert Rossol, Jürgen Wasem, Michael P. Manns, John G. McHutchison & John B. Wong. (2009) Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response. PharmacoEconomics 27:4, pages 341-354.
Crossref
Crossref
Takumi Kawaguchi, Shuji Sumie, Minoru Itou, Eitaro Taniguchi, Tsunetaka Matoba & Michio Sata. (2008) Clinical Benefits and Cost-Effectiveness of 17-Year Treatment with Low-Dose Interferon-α 2b in a Patient with Chronic Hepatitis C: A Case Report. Digestive Diseases and Sciences 54:3, pages 690-694.
Crossref
Crossref
Daniel Lavanchy. (2009) The global burden of hepatitis C. Liver International 29, pages 74-81.
Crossref
Crossref
Junichiro Nakamura, Kuriko Kobayashi, Shin-ichi Toyabe, Yutaka Aoyagi & Kouhei Akazawa. (2007) The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon ??-2b and ribavirin for chronic hepatitis C. European Journal of Gastroenterology & Hepatology 19:9, pages 733-739.
Crossref
Crossref
Hidenari Nagai, Katsuhiko Matsumaru, Kazue Shiozawa, Kouichi Momiyama, Noritaka Wakui, Masao Shinohara, Manabu Watanabe, Koji Ishii, Hiroko Nonaka, Akira Hasegawa, Tatsuo Teramoto, Wataru Yamamuro, Yasukiyo Sumino & Kazumasa Miki. (2005) Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation. Journal of Gastroenterology 40:8, pages 848-853.
Crossref
Crossref
Uwe Siebert, Gaby Sroczynski, Jürgen Wasem, Wolfgang Greiner, Ulrike Ravens-Sieberer, Pamela Aidelsburger, Bärbel M. Kurth, Monika Bullinger, J.-Matthias Graf von der Schulenburg, John B. Wong & Siegbert Rossol. (2005) Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. The European Journal of Health Economics 6:2, pages 112-123.
Crossref
Crossref
María Buti, Ramón San Miguel, Max Brosa, Juan M. Cabasés, Montserrat Medina, Miguel Angel Casado, Leslie Fosbrook & Rafael Esteban. (2005) Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. Journal of Hepatology 42:5, pages 639-645.
Crossref
Crossref
R.C Botero. (2004) Should patients with chronic hepatitis C infection be transplanted?. Transplantation Proceedings 36:5, pages 1449-1454.
Crossref
Crossref
Murray KrahnJohn B. Wong, Jenny Heathcote, Linda Scully & Leonard Seeff. (2016) Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990. Medical Decision Making 24:1, pages 20-29.
Crossref
Crossref
. (2004) Global Burden of Disease (GBD) for Hepatitis C. The Journal of Clinical Pharmacology 44:1, pages 20-29.
Crossref
Crossref
Hisayoshi Watanabe, Takafumi Saito, Haruhide Shinzawa, Kazuo Okumoto, Etsuko Hattori, Tohru Adachi, Tadashi Takeda, Kazuhiko Sugahara, Jun‐itsu Ito, Koji Saito, Hitoshi Togashi, Ryosuke Suzuki, Masahiro Hayashi, Tatsuo Miyamura, Yoshiharu Matsuura & Sumio Kawata. (2003) Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population‐based cohort study. Journal of Medical Virology 71:1, pages 56-61.
Crossref
Crossref
Gregory J Dore, Anthony J Freeman, Matthew Law & John M Kaldor. (2002) Natural History Models for Hepatitis C-Related Liver Disease: Different Disease Progression Parameters for Different Settings. Antiviral Therapy 8:5, pages 365-372.
Crossref
Crossref
EISUKE NAKASHIMA, TAKUJI FUJISAWA, AKIHIKO KIMURA, MASAYOSHI KAGE, YASUHIKO YAMATO, KOHJI MAEDA, MASAMI KUMAGAI, KOSUKE USHIJIMA, YASUHIRO YAMASHITA & TOYOJIRO MATSUISHI. (2003) Efficacy of interferon-alpha treatment in Japanese children with chronic hepatitis C. Journal of Gastroenterology and Hepatology 18:4, pages 411-414.
Crossref
Crossref
Gregory J Dore, Anthony J Freeman, Matthew Law & JohnM Kaldor. (2002) Is severe liver disease a common outcome for people with chronic hepatitisC?. Journal of Gastroenterology and Hepatology 17:4, pages 423-430.
Crossref
Crossref
. (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 90:10, pages 1562-1569.
Crossref
Crossref
Alberto R Osella, Giovanni Misciagna, Vito M Guerra, Marisa Chiloiro, Renato Cuppone, Aldo Cavallini & Alfredo Di Leo. (2000) Hepatitis C virus (HCV) infection and liver-related mortality: a population-based cohort study in southern Italy. International Journal of Epidemiology 29:5, pages 922-927.
Crossref
Crossref
Atsuo Hoshiyama, Akihiko Kimura, Takuji Fujisawa, Masayoshi KageHirohisa Kato. (2000) Clinical and Histologic Features of Chronic Hepatitis C Virus Infection After Blood Transfusion in Japanese Children. Pediatrics 105:1, pages 62-65.
Crossref
Crossref
John B Wong. (1999) Cost-effectiveness of treatments for chronic hepatitis C. The American Journal of Medicine 107:6, pages 74-78.
Crossref
Crossref
Karin Grønbæk, Henrik Bygum Krarup, Henrik Møller, Kim Krogsgaard, Maria Franzmann, Jesper Sonne, Helmer Ring-Larsen & Odd Dietrichson. (1999) Natural history and etiology of liver disease in patients with previous community-acquired acute non-A, non-B hepatitis. Journal of Hepatology 31:5, pages 800-807.
Crossref
Crossref
Motoji Sawabe, Tomio Arai, Yukiyoshi Esaki, Toshio Fukazawa & Kalyo Takubo. (2008) Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Liver 19:4, pages 335-342.
Crossref
Crossref
Reinhard H. Dennin, Jianer Wo & Zhi Chen. (1999) Hepatitis C Virus-Specific DNA Sequences in Human DNA: Differentiation by Means of Restriction Enzyme Analysis at the DNA Level of Healthy, Anti-HCV-Negative Individuals. cclm 37:6, pages 623-630.
Crossref
Crossref
Patrick G Quinn, Mazen M Jamal, John D Carey, Sanjeev Arora, Tanya Harris, David E Johnston & Amnon Sonnenberg. (1999) A Case-Control Study of The Factors Associated With Spontaneous Resolution of Hepatitis C Viremia. American Journal of Gastroenterology 94:3, pages 668-673.
Crossref
Crossref
Alfredo Alberti, Liliana Chemello & Luisa Benvegnù. (1999) Natural history of hepatitis C. Journal of Hepatology 31, pages 17-24.
Crossref
Crossref
Tsukazaki, Watanabe & Irifune. (1998) Porphyria cutanea tarda and hepatitis C virus infection. British Journal of Dermatology 138:6, pages 1015-1017.
Crossref
Crossref
Mario Pirisi, Pierluigi Toniutto, Carlo Fabris, Tiziana Lombardelli, Edmondo Falleti, Sergio G Tisminetzky, Francisco Baralle & Ettore Bartoli. (1998) Factors Associated with Serum HCV RNA Positivity in Anti-HCV Antibody Positive Intravenous Drug Users. Journal of Clinical Epidemiology 51:5, pages 423-427.
Crossref
Crossref
H. Verbaan, A. Widell, L. Bondeson, K. Andersson & S. Eriksson. (1998) Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence. Journal of Viral Hepatitis 5:1, pages 43-51.
Crossref
Crossref
Steven Shev, Amar P. Dhillon, Magnus Lindh, Zita Serléus, Rune Wejstål, Anders Widell & Gunnar Norkrans. (2008) The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver 17:5, pages 215-223.
Crossref
Crossref
Muneko Okazaki, Keisuke Hino, Kaori Fujii, Nobuyuki Kobayashi & Kiwamu Okita. (1996) Hepatic fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Digestive Diseases and Sciences 41:12, pages 2453-2458.
Crossref
Crossref
Shino SAKAI, Makoto WATANABE & Shiro FUKUMOTO. (2007) Laparoscopic Findings as a Predictor of the Efficacy of Interferon Therapy and Laparoscopic Changes in Sustained Responders after Interferon Therapy. Digestive Endoscopy 8:4, pages 293-301.
Crossref
Crossref
Byung-Il Yeh, Kwang-Hyub Han, Seung-Hee Oh, Hyon-Suk Kim, Suk-Hyun Hong, Sang-Hwan Oh & Yoon-Soo Kim. (1996) Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy. Journal of Medical Virology 49:2, pages 95-102.
Crossref
Crossref
A. Berger, H.W. Doerr, W. Preiser & B. Weber. (1996) Lack of correlation between different hepatitis C virus screening and confirmatory assays. Journal of Virological Methods 59:1-2, pages 141-146.
Crossref
Crossref
G. Gerken, P. Knolle & K.-H. Meyer zum Büschenfelde. 1996. Symposium in Immunology V. Symposium in Immunology V
77
89
.
Shino SAKAI, Makoto WATANABE, Shuichi SATO, Naruaki KOHGE, Shuji AKAGI & Shiro FUKUMOTO. (2007) Spontaneous Resolution of Chronic Hepatitis C – A Case Report. Digestive Endoscopy 7:3, pages 285-291.
Crossref
Crossref
NORIO HORIIKE, TOSHIKAZU MASUMOTO, KIMIO NAKANISHI, KOJIRO MICHITAKA, KIYOTAKA KUROSE, IZUMI OHKURA & MORIKAZU ONJI. (2008) Interferon therapy for patients more than 60 years of age with chronic hepatitis C. Journal of Gastroenterology and Hepatology 10:3, pages 246-249.
Crossref
Crossref
Stephen Porter, Crispian Scully & Lakshman Samaranayake. (1994) Viral hepatitis. Oral Surgery, Oral Medicine, Oral Pathology 78:6, pages 682-695.
Crossref
Crossref
Masao Honda, Shuichi Kaneko, Akito Sakai, Masashi Unoura, Seishi Murakami & Kenichi Kobayashi. (1994) Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 20:5, pages 1144-1151.
Crossref
Crossref
Jacques Pillot, Michel Rioche & Yamina Lazizi. (1994) ELISA in serodiagnosis of HCV infection. FEMS Microbiology Reviews 14:3, pages 221-227.
Crossref
Crossref
Michael C. Kew. (1994) Hepatitis C virus and hepatocellualr carcinoma. FEMS Microbiology Reviews 14:3, pages 211-219.
Crossref
Crossref
Sten Iwarson. (1994) The natural course of chronic hepatitis C. FEMS Microbiology Reviews 14:3, pages 201-204.
Crossref
Crossref
Akihiro Matsumoto, Eiji Tanaka, Toshio Suzuki, Hiroyuki Ogata & Kendo Kiyosawa. (1994) Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C. Digestive Diseases and Sciences 39:6, pages 1273-1280.
Crossref
Crossref
D. Tan, S. W. K. Im, W. W. Peng & M. H. Ng. (1994) Follow-up study of acute hepatitis C. Archives of Virology 138:1-2, pages 71-84.
Crossref
Crossref